Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. 2019

Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
Department of Translational Medicine, Federico II University of Naples, 80131 Naples, Italy. mi_longo@libero.it.

Obesity is a critical risk factor for the development of type 2 diabetes (T2D), and its prevalence is rising worldwide. White adipose tissue (WAT) has a crucial role in regulating systemic energy homeostasis. Adipose tissue expands by a combination of an increase in adipocyte size (hypertrophy) and number (hyperplasia). The recruitment and differentiation of adipose precursor cells in the subcutaneous adipose tissue (SAT), rather than merely inflating the cells, would be protective from the obesity-associated metabolic complications. In metabolically unhealthy obesity, the storage capacity of SAT, the largest WAT depot, is limited, and further caloric overload leads to the fat accumulation in ectopic tissues (e.g., liver, skeletal muscle, and heart) and in the visceral adipose depots, an event commonly defined as "lipotoxicity." Excessive ectopic lipid accumulation leads to local inflammation and insulin resistance (IR). Indeed, overnutrition triggers uncontrolled inflammatory responses in WAT, leading to chronic low-grade inflammation, therefore fostering the progression of IR. This review summarizes the current knowledge on WAT dysfunction in obesity and its associated metabolic abnormalities, such as IR. A better understanding of the mechanisms regulating adipose tissue expansion in obesity is required for the development of future therapeutic approaches in obesity-associated metabolic complications.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000273 Adipose Tissue Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. Fatty Tissue,Body Fat,Fat Pad,Fat Pads,Pad, Fat,Pads, Fat,Tissue, Adipose,Tissue, Fatty
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050151 Subcutaneous Fat Fatty tissue under the SKIN through out the body. Adipose Tissue, Subcutaneous,Fat, Subcutaneous,Subcutaneous Adipose Tissue,Fats, Subcutaneous,Subcutaneous Fats
D050156 Adipogenesis The differentiation of pre-adipocytes into mature ADIPOCYTES. Adipogeneses

Related Publications

Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
January 2015, Critical reviews in clinical laboratory sciences,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
March 2021, American journal of physiology. Cell physiology,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
April 2013, Best practice & research. Clinical endocrinology & metabolism,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
October 2012, Metabolic syndrome and related disorders,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
January 2022, Frontiers in immunology,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
April 2014, Diabetes,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
June 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
November 2014, Diabetes,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
January 2012, Adipocyte,
Michele Longo, and Federica Zatterale, and Jamal Naderi, and Luca Parrillo, and Pietro Formisano, and Gregory Alexander Raciti, and Francesco Beguinot, and Claudia Miele
December 2006, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!